Federal grants to Neurexis Therapeutics, Inc.
Neurexis Therapeutics, Inc. in Aurora, Colorado received $4.2 million in federal grants from fiscal 2021 to 2025, across 3 awards. Its largest program was Extramural Research Programs in the Neurosciences and Neurological Disorders, with $4.2 million. In fiscal 2025 it was awarded $2.1 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$4.2 million
- Awards3
- Awarded in FY 2025$2.1 million
- Largest award$2.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $496,145 |
| FY 2022 | 0 | $0 |
| FY 2023 | 1 | $299,550 |
| FY 2024 | 2 | $1.2 million |
| FY 2025 | 2 | $2.1 million |
Programs that fund Neurexis Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 3 | $4.2 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 3 | $4.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Ind-enabling studies for a potent and efficient neuroprotective drug - project summary/abstract global cerebral ischemia (GCI) afflicts over 700,000 americans each year and often results in permanent cognitive impairment or death. Here, we will complete ind-enabling studies for a therapeutic strateg | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 10, 2024 | $2.8 million |
| Comparative testing of TATCN19O for neuroprotection in rodent tmcao - project summary/abstract focal cerebral ischemia (STROKE) afflicts nearly 800,000 americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have larg | Extramural Research Programs in the Neurosciences and Neurological Disorders | April 12, 2023 | $898,650 |
| Preparing for ind-enabling safety studies for a potent and efficient neuroprotective drug. - project summary/abstract the CA2+/calmodulin-dependent protein kinase II (CAMKII) is a central mediator of two opposing forms of nmda- receptor (NMDAR)-dependent synaptic plasticity: long-term potentiation ( | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 22, 2021 | $496,145 |
Questions people ask
How much federal grant money does Neurexis Therapeutics, Inc. get?
$4.2 million in 3 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Neurexis Therapeutics, Inc. the most?
The Department of Health and Human Services, with $4.2 million in 3 awards.
What is Neurexis Therapeutics, Inc.'s largest federal grant?
$2.8 million under Extramural Research Programs in the Neurosciences and Neurological Disorders, with its first action in the period on September 10, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Aurora
- The Regents of the University of Colorado
- Aurora, City of
- Children's Hospital Colorado
- State Board for Community Colleges and Occupational Education
- Aurora Comprehensive Community Mental Health Center, Inc.
- City of Aurora Colorado
- Joint School District No 28-J of the Counties of Adams & Arapahoe
- Z Biotech, LLC
Largest federal grant recipients in Colorado · Federal grants in Colorado